CA2986349A1 - Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions - Google Patents

Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions

Info

Publication number
CA2986349A1
CA2986349A1 CA2986349A CA2986349A CA2986349A1 CA 2986349 A1 CA2986349 A1 CA 2986349A1 CA 2986349 A CA2986349 A CA 2986349A CA 2986349 A CA2986349 A CA 2986349A CA 2986349 A1 CA2986349 A1 CA 2986349A1
Authority
CA
Canada
Prior art keywords
crystalline form
depicted
tetrahydro
disease
anavex19
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2986349A
Other languages
English (en)
French (fr)
Inventor
Peter York
Lucy Anne Leonard
Daniel Mark LEDGER
Linda Sharon Daintree
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Publication of CA2986349A1 publication Critical patent/CA2986349A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
CA2986349A 2015-07-22 2016-07-19 Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions Pending CA2986349A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195486P 2015-07-22 2015-07-22
US62/195,486 2015-07-22
PCT/IB2016/001181 WO2017013498A2 (en) 2015-07-22 2016-07-19 Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CA2986349A1 true CA2986349A1 (en) 2017-01-26

Family

ID=57833871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2986349A Pending CA2986349A1 (en) 2015-07-22 2016-07-19 Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions

Country Status (7)

Country Link
US (4) US10413519B2 (https=)
EP (2) EP3325456B1 (https=)
JP (3) JP7304043B2 (https=)
CN (2) CN108026059A (https=)
CA (1) CA2986349A1 (https=)
HK (1) HK1247926A1 (https=)
WO (1) WO2017013498A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026059A (zh) * 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
JP2020523417A (ja) * 2017-06-14 2020-08-06 アナベックス ライフ サイエンス コーポレイション アルツハイマー病の治療のためのａｎａｖｅｘ２−７３
WO2019200345A1 (en) * 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
EP3794345B1 (en) 2018-05-18 2025-02-26 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
US12473268B2 (en) 2020-02-04 2025-11-18 Assia Chemical Industries, Ltd. Solid state forms of Blarcamesine salts
EP4516782A4 (en) 2022-04-29 2025-06-11 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF BLARCAMESIN HYDROCHLORIDE, ITS PREPARATION PROCESS AND ITS USE
US12018005B1 (en) * 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
GR1002616B (el) 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB9804379D0 (en) 1998-03-02 1998-04-22 Bradford Particle Design Ltd Method of particle formation
GB9810559D0 (en) 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
TW586963B (en) 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GR1006794B (el) * 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
GB201005623D0 (en) * 2010-04-01 2010-05-19 Vantia Ltd New polymorph
GR1007686B (el) * 2011-07-08 2012-09-12 Αλεξανδρος Δημητριου Βαμβακιδης Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης
CN103539783A (zh) 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
GR1008233B (el) 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
CN108026059A (zh) * 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
HK1247847A1 (zh) 2015-07-22 2018-10-05 阿纳韦克斯生命科学公司 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
HK1247926A1 (zh) 2018-10-05
EP3325456A4 (en) 2019-01-23
US11661405B2 (en) 2023-05-30
JP7304043B2 (ja) 2023-07-06
US10966952B2 (en) 2021-04-06
US20190350892A1 (en) 2019-11-21
US20230278973A1 (en) 2023-09-07
EP4616852A2 (en) 2025-09-17
US20180169060A1 (en) 2018-06-21
EP3325456A2 (en) 2018-05-30
JP2023083528A (ja) 2023-06-15
WO2017013498A3 (en) 2017-03-02
JP7492781B2 (ja) 2024-05-30
JP2021073300A (ja) 2021-05-13
US20210220321A1 (en) 2021-07-22
US10413519B2 (en) 2019-09-17
CN119390667A (zh) 2025-02-07
JP2018524307A (ja) 2018-08-30
WO2017013498A2 (en) 2017-01-26
CN108026059A (zh) 2018-05-11
EP4616852A3 (en) 2025-10-22
EP3325456B1 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
CA2986349A1 (en) Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
KR20170085590A (ko) 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도
CN102151261A (zh) [3.2.0]杂环化合物及其类似物在癌症、炎症和感染性疾病治疗中的应用
JP2018511580A (ja) イブルチニブの多形体
AU2014259029B2 (en) Polymorphic forms of nilotinib hydrochloride
CN101711154A (zh) 氨基甲酸酯化合物
Fitriani et al. Solid Dispersion of Usnic acid-HPMC 2910 Prepared by Spray drying and Freeze drying Techniques.
CA2645211A1 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
Li et al. Higher quality quercetin sustained release ethyl cellulose nanofibers fabricated using a spinneret with a Teflon nozzle
Zhao et al. Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO2 Anti‐Solvent Process
CN104530147B (zh) 一种从裸花紫珠叶中提取制备毛蕊花糖苷标准品的方法
CN101322713A (zh) 天麻素在制备半胱氨酸蛋白酶-3活性抑制剂中的应用
HK40121350A (zh) 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物
CN106029632B (zh) 酰胺衍生物
CN105793247B (zh) 咪唑甲酰胺类及其作为faah抑制剂的用途
CN107226784B (zh) 超临界反溶剂造粒技术制备扑热息痛与甜菜碱共晶的方法
CN110167917B (zh) 一种具有抗癌作用的化合物及其制备方法和应用
Nhan et al. Improvement of gliclazide dissolution rate using in situ micronization technique
CN106336363A (zh) 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN104130255B (zh) 一种吡唑并吡啶类化合物及其制备方法
Vennapu et al. Polymorphic characterization of tramadol hydrochloride using differential scanning calorimetry
WO2015170827A1 (ko) 실로도신 감마형 결정의 제조방법
HK40102916A (zh) 脂质纳米材料及其用途
CN108530460A (zh) 鬼臼毒素-氯尼达明缀合物及其合成方法和医药用途
CN107903270A (zh) 一种治疗男性勃起功能障碍的枸橼酸西地那非化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210526

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240725

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250527

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250527

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250711

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250711

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250929

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251002

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20251008

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251104

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251104

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260303